查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439939

HPV 檢測/巴氏試驗 - 全球市場考量、競爭狀況、市場預測 (2030)

HPV Testing and Pap Test - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2023年全球HPV檢測/巴氏試驗市場規模為33億美元，到2030年將達47.2億美元，預計2024-2030年期間複合年增長率為6.17%。由於子宮頸癌盛行率上升和世界各地篩檢計畫的增加等因素，預計該市場將蓬勃發展。對 HPV 檢測和巴氏抹片檢測的認識的提高也是預測期內（2024-2030 年）HPV 檢測和巴氏抹片檢測市場收入成長的因素之一。

HPV 檢測/巴氏試驗市場動態

HPV 檢測和巴氏抹片檢測市場的主要驅動因素之一是子宮頸癌盛行率的上升。子宮頸癌是一種始於子宮頸細胞的癌症，子宮頸是子宮與陰道相連的下部。子宮頸癌患者數量的增加導致人們對預先篩檢和檢測的意識增強，從而導致 HPV 檢測和巴氏抹片檢測市場的成長。

根據世界衛生組織2022年公佈的數據，子宮頸癌是全球女性第四大常見癌症，預計2020年新增病例為60.4萬例，死亡人數為34.2萬人。2020年全球約90%的新增病例和死亡病例發生在低收入和中等收入國家。

因此，育齡婦女子宮頸癌盛行率不斷上升，增加了對 HPV 檢測/巴氏抹片檢測的需求，預計將在 2024-2030 年預測期內推動市場成長。

此外，政府機構加強提高人們對子宮頸癌的認識，進一步擴大了 HPV 篩檢市場，並推動了 HPV 檢測/巴氏抹片檢查市場的成長。

例如，2020年World Health Assembly通過了一項全球策略，加速消除子宮頸癌這個公共衛生問題。消除子宮頸癌的定義是達到每年每 10 萬名婦女中子宮頸癌病例少於 4 例的國家。為了在 21 世紀末達到這一門檻，世衛組織設定了到 2030 年 70% 的女性在 35 歲時接受高性能檢測的目標，並在 45 歲時再次接受高水平檢測。Masu。因此，在 2024 年至 2030 年的預測期內，將推動 HPV 檢測和巴氏抹片檢測市場的成長。

此外，HPV 篩檢產品開發的進步正在為 HPV 檢測和巴氏抹片檢測市場的成長帶來利潤豐厚的成長機會。Qiagen 等公司提供利用先進技術檢測 HPV DNA 的測試，例如 Capture 2 測試，可檢測子宮頸樣本中是否存在 13 種高危險 HPV 類型。

COVID-19 對 HPV 檢測和巴氏抹片檢測市場產生了負面影響。COVID-19 法規已使許多國家處於封鎖狀態，導致衛生服務下降，包括各種疾病的診斷。2020 年，隨著COVID-19 大流行在全球升級，包括癌症篩檢在內的許多不同的選擇性醫療程序被推遲，以優先考慮其他緊急需求並降低傳播COVID-19 的風險。事實證明確實如此。因此，癌症篩檢顯著下降，影響了 HPV 檢測和巴氏抹片檢測市場的收入成長。

此外，推出針對該病毒的HPV疫苗以確保減少子宮頸癌是HPV檢測和巴氏試驗市場成長的限制因素之一，預計該市場將在2024-2030年預測期內成長。有影響

HPV檢測/巴氏抹片檢測市場區隔分析

在HPV檢測和巴氏試驗市場的應用領域中，子宮頸癌在2023年佔據最大的市場佔有率。這被認為是由於近年來子宮頸癌篩檢測試的增加。

本報告研究和分析了全球 HPV 檢測和巴氏檢測市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

目錄

第一章 HPV 檢測/巴氏抹片檢測市場報告簡介

第二章 HPV 檢測與巴氏抹片檢測市場摘要

  • 調查範圍
  • 市場概況
  • 競爭評估

第三章 HPV檢測/巴氏抹片檢測市場主要因素分析

  • HPV檢測和巴氏試驗市場的驅動因素
  • HPV檢測/巴氏抹片檢測市場的抑制因素與挑戰
  • HPV 檢測/巴氏抹片檢測市場機會

第四章 HPV 檢測與巴氏抹片檢測市場的波特五力分析

第五章 COVID-19對HPV檢測與巴氏抹片檢測市場的影響分析

第六章 HPV檢測/巴氏試驗市場佈局

  • 按測試類型
    • 初級 HPV 檢測
    • 玻璃組合檢查
    • 巴氏抹片檢查
  • 按用途
    • 子宮頸癌
    • 陰道癌
    • 其他
  • 按技術類型
    • 聚合酶鏈反應
  • 按最終用戶
    • 醫院、診所
    • 診斷實驗室
  • 區域
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第七章 HPV 檢測/巴氏抹片檢測市場公司及產品概況

  • Arbor Vita Corporation
  • Danaher Corporation (Cepheid)
  • Seegene Inc.
  • Becton, Dickinson and Company
  • TruScreen
  • Abbott Laboratories
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • OncoHealth Corporation
  • Takara Bio Inc.
  • Promega Corporation
  • Quest Diagnostics
  • Femasys Inc.
  • Mylab Discovery Solutions Pvt Ltd.
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • Nurx

第8章 KOL觀點

第9章 專案方法

第10章 關於 DelveInsight

第11章 免責聲明與聯絡我們

Product Code: DIMDCL0620

HPV Testing And PAP Test Market By Test Type (Primary HPV Testing, Co-Testing, And Pap Test), By Application (Cervical Cancer, Vaginal Cancer, And Others), By Technology Type (Polymerase Chain Reaction, And Others), By End-User (Hospitals And Clinics, Diagnostic Laboratories, And Others) by geography is estimated to register a growth at a remarkable CAGR forecast during 2024-2030 owing to rising prevalence of cervical cancer and increased awareness

The global HPV testing and Pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030. The HPV testing and Pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

HPV Testing And PAP Test Market Dynamics:

One of the major factors which are driving the HPV testing and pap test market is the rising prevalence of cervical cancer. Cervical cancer is a type of cancer that occurs in the cells of the cervix which is the lower part of the uterus that connects to the vagina. The increase in the rate of cervical cases has created an awareness for prior screening and testing which has led to a growth in the HPV testing and pap test market.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries.

Thus, the increasing prevalence of cervical cancer among women of reproductive age is increasing the demand for HPV testing and pap test, which is anticipated to boost the market's growth over the forecast period from 2024-2030.

Moreover, increasing initiatives by government bodies to create awareness for cervical cancer has further increased the market for HPV screening thereby fueling the market growth for HPV testing and pap test.

For instance, the World Health Assembly in 2020 adopted the global strategy to accelerate the elimination of cervical cancer as a public health problem. The definition of elimination of cervical cancer has been set up as a country reaching the threshold of fewer than 4 cases of cervical cancer per 100,000 women per year. To reach this threshold by the end of the 21st century, WHO has set up a target to be reached by 2030 by screening 70% of women with a high-performance test by 35, and again by 45 years of age. Thus, driving the growth of the HPV testing and pap test market in the forecast period of 2024-2030.

Furthermore, advancement in product development for the screening of HPV has led to lucrative growth opportunities in the HPV testing and pap test market growth. Companies like Qiagen are having technologically advanced tests that detect HPV DNA such as the Capture 2 test, which detects the presence of 13 high-risk HPV types in the cervical sample.

COVID-19 has adversely impacted the HPV testing and pap test market. Due to COVID-19 restrictions, many countries were in lockdown leading to a decline in healthcare services, including the diagnosis of various diseases. In 2020, with the rising COVID-19 pandemic globally, various elective medical procedures, including cancer screening, were found to be largely put on hold to prioritize other urgent needs and reduce the risk of the spread of COVID-19. This has shown a substantial decline in cancer screening, thereby affecting the revenue growth of the HPV testing and pap test market.

Furthermore, the launch of the HPV vaccine against the virus to ensure the decline in cervical cancer is one of the restraining factors to the growth of the HPV testing and pap test market that will impact the market growth during the forecast period from 2024-2030.

HPV Testing And PAP Test Market Segment Analysis:

HPV testing and Pap test market by Test Type (Primary HPV Testing, Co-Testing, and Pap Test), by Application (Cervical Cancer, Vaginal Cancer, and Others), by Technology Type (Polymerase Chain Reaction, and Others), by End-User (Hospitals And Clinics, Diagnostic Laboratories, and Others), by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the application segment of the HPV testing and pap test market, cervical cancer accounted for the largest market share in the year 2023. This can be ascribed to the increase in cervical cancer screening tests lately.

Cervical cancer screening is an essential part of a woman's routine healthcare. For women of age 30 years and above, an HPV test is recommended for detection. Almost 95% of cervical cancer causes the causative organisms estimated to be the HP virus. The screening helps identify precancerous lesions caused by HPV so they can be removed to prevent invasive cancers from developing.

The data published by WHO in 2022 states that cervical cancer is the fourth most common cancer among women globally, with an estimated 604,000 new cases and 342,000 deaths in 2020. About 90% of the new cases and deaths worldwide in 2020 occurred in low- and middle-income countries. Therefore, the WHO in 2020 adopted the Global strategy towards eliminating cervical cancer as a public health problem and recommends a comprehensive approach to cervical cancer prevention and control.

Furthermore, in September 2018, the Ministers of Health of the Americas, at the Pan American Health Organization initiated an "Its Time to End Cervical Cancer" campaign to reduce cervical cancer by 2030. To accomplish this, the plan aims to strengthen primary prevention through information and education and HPV vaccination, as well as improve cervical cancer screening and treatment of precancerous lesions, and strengthen access to cancer diagnosis, treatment, rehabilitation, and palliative care.

All these increases in cervical cancer numbers and subsequent awareness programs for the same correspond to the increased market share of the segment, thereby increasing the market growth for the HPV testing and pap test market.

North America is expected to dominate the overall HPV Testing And PAP Test Market:

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

As per CDC 2022 data, each year in the US, about 13,000 new cases of cervical cancer are diagnosed and about 4,000 women die of this cancer. Hispanic women have the highest rates of developing cervical cancer, and Black women have the highest rates of dying from cervical cancer. Therefore, such numbers indicate considerable market growth in this region.

Therefore, with the rising cases of cervical cancer in the region, the government has adopted various awareness programs to decrease the incidence rate of the disease. A few of them are the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) for breast and cervical cancer screening, the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force (USPSTF), for cervical cancer screening. This is one of the major factors expected to drive the North American market for HPV testing and Pap test during the forecast period.

Apart from this, various research and development activities in the North American region for the HPV testing and pap test market are also key factors for the dominance in the market share.

For instance, in 2019, researchers at Massachusetts General Hospital's Center for Systems Biology and Harvard Medical School, Boston presented a novel screening handheld device that uses Artificial Intelligence (AI) for HPV detection. The novel device detects the presence of HPV strains 16 and 18 in a turnaround time of 2 hours.

Therefore, the above-mentioned factors are expected to bolster the growth of the HPV testing and pap test market in the North American region during the forecast period of 2024-2030.

HPV Testing And PAP Test Market Key Players:

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

Recent Developmental Activities In The HPV Testing And PAP Test Market:

In September 2022, Diagnostics player Mylab Discovery Solutions announced the launch of the 'PathoDetect HPV Detection Test', a real-time PCR-based screening solution to detect high-risk types of human papillomaviruses in individuals.

In June 2022, Roche announced the launch of an HPV self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analyzed with the Roche Cobas HPV test on a Roche molecular instrument.

Key Takeaways from the HPV Testing And PAP Test Market Report Study

  • Market size analysis for current HPV testing and pap test market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the HPV testing and pap test market.
  • Top key product developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
  • Key companies dominating the global HPV testing and pap test market.
  • Various opportunities available for the other competitor in the HPV testing and pap test market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current HPV testing and pap test market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for HPV testing and pap test market growth in the coming future?

Target Audience who can be benefited from this HPV Testing And PAP Test Market Report Study

  • HPV testing and pap test products providers
  • Research organizations and consulting companies
  • HPV testing and pap test -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in HPV testing and pap test
  • Various distribution channels who want to know more about the HPV testing and pap test market and the latest product innovations in the HPV testing and pap test market.

Frequently Asked Questions for HPV Testing and The PAP Test Market:

1. What are HPV testing and pap test?

The HPV test looks for the virus (human papillomavirus) that can cause cell changes on the cervix causing cervical cancer. Whereas, the Pap test (or Pap smear) looks for precancers and cell changes on the cervix that might become cervical cancer if they are not treated appropriately. These tests include microscopic observation of specimens.

2. What is the market for global HPV testing and pap test?

The global HPV testing and pap test market was valued at USD 3.30 billion in 2023, growing at a CAGR of 6.17% during the forecast period from 2024 to 2030 to reach USD 4.72 billion by 2030.

3. What are the drivers for the global HPV testing and pap test market?

The HPV testing and pap test market is anticipated to witness prosperity owing to factors such rising prevalence of cervical cancer globally and the increasing number of screening programs. An increase in awareness towards HPV and Pap tests is another factor that will result in appreciable revenue growth in the HPV testing and pap test market during the forecast period (2024-2030).

4. Who are the key players operating in the global HPV testing and pap test market?

Some of the key market players operating in the HPV testing and pap test market include Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, OncoHealth Corporation, Takara Bio Inc., Promega Corporation, Quest Diagnostics, Femasys Inc., Mylab Discovery Solutions Pvt Ltd., Thermo Fisher Scientific Inc., bioMerieux SA, Nurx and others.

5. Which region has the highest share in the HPV testing and pap test market?

Among all the regions, North America is expected to lead in revenue generation in the global HPV testing and pap test market. The highest growth in the region is registered due to the reasons such as rising cases of cervical cancer, numerous awareness initiatives, and high research and development activities in the arena which pay the way for the launch of advanced products in the region.

Table of Contents

1. HPV testing and pap test market Report Introduction

2. HPV testing and pap test market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. HPV testing and pap test market Key Factors Analysis

  • 3.1. HPV testing and pap test market Drivers
    • 3.1.1. Rising prevalence of cervical cancer
    • 3.1.2. Increase in awareness
    • 3.1.3. Increase in the number of screening programs
  • 3.2. HPV testing and pap test market Restraints and Challenges
    • 3.2.1. Launch of vaccine for cervical cancer prevention
  • 3.3. HPV testing and pap test market Opportunities
    • 3.3.1. Research and development for new diagnostic technologies
    • 3.3.2. The opportunistic market for Low and Middle-Income Countries

4. HPV testing and pap test market Porter's Five Forces Analysis

  • 4.1 .Bargaining Power of Suppliers
  • 4.2 .Bargaining Power of Consumers
  • 4.3 .Threat of New Entrants
  • 4.4 .Threat of Substitutes
  • 4.5 .Competitive Rivalry

5. COVID-19 Impact Analysis on HPV testing and pap test market

6. HPV testing and pap test market Layout

  • 6.1. By Test Type
    • 6.1.1. Primary HPV Testing
    • 6.1.2. Glass Co-Testing
    • 6.1.3. Pap Test
  • 6.2. By Application
    • 6.2.1. Cervical cancer
    • 6.2.2. Vaginal cancer
    • 6.2.3. Others
  • 6.3. By Technology Type
    • 6.3.1. Polymerase chain reaction
    • 6.3.2. Others
  • 6.4. By End User
    • 6.4.1. Hospital and clinics
    • 6.4.2. Diagnostic labs
    • 6.4.3. Others
  • 6.5. By Geography
    • 6.5.1. North America
      • 6.5.1.1. United States HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.2. Canada HPV testing and pap test market in USD million (2021-2030)
      • 6.5.1.3. Mexico HPV testing and pap test market in USD million (2021-2030)
    • 6.5.2. Europe
      • 6.5.2.1. France HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.2. Germany HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.3. United Kingdom HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.4. Italy HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.5. Spain HPV testing and pap test market in USD million (2021-2030)
      • 6.5.2.6. Rest of Europe HPV testing and pap test market in USD million (2021-2030)
    • 6.5.3. Asia-Pacific
      • 6.5.3.1. China HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.2. Japan HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.3. India HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.4. Australia HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.5. South Korea HPV testing and pap test market in USD million (2021-2030)
      • 6.5.3.6. Rest of the Asia Pacific HPV testing and pap test market in USD million (2021-2030)
    • 6.5.4. Rest of the World (RoW)
      • 6.5.4.1. Middle East HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.2. Africa HPV testing and pap test market in USD million (2021-2030)
      • 6.5.4.3. South America HPV testing and pap test market in USD million (2021-2030)

7. HPV testing and pap test market Company and Product Profiles

  • 7.1. Arbor Vita Corporation
    • 7.1.1. Company Overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Financial Overview
    • 7.1.4. Product Listing
    • 7.1.5. Entropy
  • 7.2. Danaher Corporation (Cepheid)
    • 7.2.1. Company Overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Financial Overview
    • 7.2.4. Product Listing
    • 7.2.5. Entropy
  • 7.3. Seegene Inc.
    • 7.3.1. Company Overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Financial Overview
    • 7.3.4. Product Listing
    • 7.3.5. Entropy
  • 7.4. Becton, Dickinson and Company
    • 7.4.1. Company Overview
    • 7.4.2. Company Snapshot
    • 7.4.3. Financial Overview
    • 7.4.4. Product Listing
    • 7.4.5. Entropy
  • 7.5. TruScreen
    • 7.5.1. Company Overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Financial Overview
    • 7.5.4. Product Listing
    • 7.5.5. Entropy
  • 7.6. Abbott Laboratories
    • 7.6.1. Company Overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Financial Overview
    • 7.6.4. Product Listing
    • 7.6.5. Entropy
  • 7.7. Hologic Inc.
    • 7.7.1. Company Overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Financial Overview
    • 7.7.4. Product Listing
    • 7.7.5. Entropy
  • 7.8. Qiagen NV
    • 7.8.1. Company Overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Financial Overview
    • 7.8.4. Product Listing
    • 7.8.5. Entropy
  • 7.9. F. Hoffmann-La Roche AG
    • 7.9.1. Company Overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Financial Overview
    • 7.9.4. Product Listing
    • 7.9.5. Entropy
  • 7.10. OncoHealth Corporation
    • 7.10.1. Company Overview
    • 7.10.2. Company Snapshot
    • 7.10.3. Financial Overview
    • 7.10.4. Product Listing
    • 7.10.5. Entropy
  • 7.11. Takara Bio Inc.
    • 7.11.1. Company Overview
    • 7.11.2. Company Snapshot
    • 7.11.3. Financial Overview
    • 7.11.4. Product Listing
    • 7.11.5. Entropy
  • 7.12. Promega Corporation
    • 7.12.1. Company Overview
    • 7.12.2. Company Snapshot
    • 7.12.3. Financial Overview
    • 7.12.4. Product Listing
    • 7.12.5. Entropy
  • 7.13. Quest Diagnostics
    • 7.13.1. Company Overview
    • 7.13.2. Company Snapshot
    • 7.13.3. Financial Overview
    • 7.13.4. Product Listing
    • 7.13.5. Entropy
  • 7.14. Femasys Inc.
    • 7.14.1. Company Overview
    • 7.14.2. Company Snapshot
    • 7.14.3. Financial Overview
    • 7.14.4. Product Listing
    • 7.14.5. Entropy
  • 7.15. Mylab Discovery Solutions Pvt Ltd.
    • 7.15.1. Company Overview
    • 7.15.2. Company Snapshot
    • 7.15.3. Financial Overview
    • 7.15.4. Product Listing
    • 7.15.5. Entropy
  • 7.16. Thermo Fisher Scientific Inc
    • 7.16.1. Company Overview
    • 7.16.2. Company Snapshot
    • 7.16.3. Financial Overview
    • 7.16.4. Product Listing
    • 7.16.5. Entropy
  • 7.17. bioMerieux SA
    • 7.17.1. Company Overview
    • 7.17.2. Company Snapshot
    • 7.17.3. Financial Overview
    • 7.17.4. Product Listing
    • 7.17.5. Entropy
  • 7.18. Nurx
    • 7.18.1. Company Overview
    • 7.18.2. Company Snapshot
    • 7.18.3. Financial Overview
    • 7.18.4. Product Listing
    • 7.18.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Table 3: HPV testing and pap test market in Global (2021-2030)
  • Table 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Table 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Table 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Table 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Table 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Table 9: HPV testing and pap test market in North America (2021-2030)
  • Table 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Table 11: HPV testing and pap test market in the US (2021-2030)
  • Table 12: HPV testing and pap test market in Canada (2021-2030)
  • Table 13: HPV testing and pap test market in Mexico (2021-2030)
  • Table 14: HPV testing and pap test market in Europe (2021-2030)
  • Table 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Table 16: HPV testing and pap test market in France (2021-2030)
  • Table 17: HPV testing and pap test market in Germany (2021-2030)
  • Table 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Table 19: HPV testing and pap test market in Italy (2021-2030)
  • Table 20: HPV testing and pap test market in Spain (2021-2030)
  • Table 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Table 22: HPV testing and pap test market in APAC (2021-2030)
  • Table 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Table 24: HPV testing and pap test market in China (2021-2030)
  • Table 25: HPV testing and pap test market in Japan (2021-2030)
  • Table 26: HPV testing and pap test market in India (2021-2030)
  • Table 27: HPV testing and pap test market in Australia (2021-2030)
  • Table 28: HPV testing and pap test market in South Korea (2021-2030)
  • Table 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Table 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Table 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Table 32: HPV testing and pap test market in Middle East (2021-2030)
  • Table 33: HPV testing and pap test market in Africa (2021-2030)
  • Table 34: HPV testing and pap test market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on HPV testing and pap test market
  • Figure 3: HPV testing and pap test market in Global (2021-2030)
  • Figure 4: HPV testing and pap test market in Global by Test Type (2021-2030)
  • Figure 5: HPV testing and pap test market in Global by Application (2021-2030)
  • Figure 6: HPV testing and pap test market in Global by Technology Type (2021-2030)
  • Figure 7: HPV testing and pap test market in Global by End User (2021-2030)
  • Figure 8: HPV testing and pap test market in Global by Geography (2021-2030)
  • Figure 9: HPV testing and pap test market in North America (2021-2030)
  • Figure 10: HPV testing and pap test market in North America by Country (2021-2030)
  • Figure 11: HPV testing and pap test market in the US (2021-2030)
  • Figure 12: HPV testing and pap test market in Canada (2021-2030)
  • Figure 13: HPV testing and pap test market in Mexico (2021-2030)
  • Figure 14: HPV testing and pap test market in Europe (2021-2030)
  • Figure 15: HPV testing and pap test market in Europe by Country (2021-2030)
  • Figure 16: HPV testing and pap test market in France (2021-2030)
  • Figure 17: HPV testing and pap test market in Germany (2021-2030)
  • Figure 18: HPV testing and pap test market in the United Kingdom (2021-2030)
  • Figure 19: HPV testing and pap test market in Italy (2021-2030)
  • Figure 20: HPV testing and pap test market in Spain (2021-2030)
  • Figure 21: HPV testing and pap test market in Rest of Europe (2021-2030)
  • Figure 22: HPV testing and pap test market in APAC (2021-2030)
  • Figure 23: HPV testing and pap test market in APAC by Country (2021-2030)
  • Figure 24: HPV testing and pap test market in China (2021-2030)
  • Figure 25: HPV testing and pap test market in Japan (2021-2030)
  • Figure 26: HPV testing and pap test market in India (2021-2030)
  • Figure 27: HPV testing and pap test market in Australia (2021-2030)
  • Figure 28: HPV testing and pap test market in South Korea (2021-2030)
  • Figure 29: HPV testing and pap test market in Rest of APAC (2021-2030)
  • Figure 30: HPV testing and pap test market in Rest of World (2021-2030)
  • Figure 31: HPV testing and pap test market in RoW by Region (2021-2030)
  • Figure 32: HPV testing and pap test market in Middle East (2021-2030)
  • Figure 33: HPV testing and pap test market in Africa (2021-2030)
  • Figure 34: HPV testing and pap test market in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Marker Opportunities
  • Figure 38: PORTER'S Five Force Analysis